JP2019516765A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516765A5
JP2019516765A5 JP2018561686A JP2018561686A JP2019516765A5 JP 2019516765 A5 JP2019516765 A5 JP 2019516765A5 JP 2018561686 A JP2018561686 A JP 2018561686A JP 2018561686 A JP2018561686 A JP 2018561686A JP 2019516765 A5 JP2019516765 A5 JP 2019516765A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561686A
Other languages
English (en)
Japanese (ja)
Other versions
JP7141108B2 (ja
JP2019516765A (ja
Filing date
Publication date
Priority claimed from GBGB1609222.3A external-priority patent/GB201609222D0/en
Application filed filed Critical
Publication of JP2019516765A publication Critical patent/JP2019516765A/ja
Publication of JP2019516765A5 publication Critical patent/JP2019516765A5/ja
Application granted granted Critical
Publication of JP7141108B2 publication Critical patent/JP7141108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561686A 2016-05-25 2017-05-25 医薬製剤 Active JP7141108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1609222.3A GB201609222D0 (en) 2016-05-25 2016-05-25 Pharmaceutical formulation
GB1609222.3 2016-05-25
PCT/GB2017/051494 WO2017203270A1 (en) 2016-05-25 2017-05-25 Pharmaceutical formulation

Publications (3)

Publication Number Publication Date
JP2019516765A JP2019516765A (ja) 2019-06-20
JP2019516765A5 true JP2019516765A5 (https=) 2020-07-02
JP7141108B2 JP7141108B2 (ja) 2022-09-22

Family

ID=56369959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561686A Active JP7141108B2 (ja) 2016-05-25 2017-05-25 医薬製剤

Country Status (25)

Country Link
US (2) US10973821B2 (https=)
EP (1) EP3463365B1 (https=)
JP (1) JP7141108B2 (https=)
KR (1) KR102464150B1 (https=)
CN (1) CN109982704B (https=)
AU (1) AU2017270942B2 (https=)
CA (1) CA3024771A1 (https=)
CY (1) CY1124733T1 (https=)
DK (1) DK3463365T3 (https=)
ES (1) ES2888951T3 (https=)
GB (1) GB201609222D0 (https=)
HR (1) HRP20211795T1 (https=)
HU (1) HUE056129T2 (https=)
IL (1) IL263167B (https=)
LT (1) LT3463365T (https=)
MA (1) MA45126A (https=)
MX (1) MX382199B (https=)
MY (1) MY197663A (https=)
PL (1) PL3463365T3 (https=)
PT (1) PT3463365T (https=)
RU (1) RU2760681C2 (https=)
SG (1) SG11201810323RA (https=)
SI (1) SI3463365T1 (https=)
WO (1) WO2017203270A1 (https=)
ZA (1) ZA201807851B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2021222045A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
CN113429396A (zh) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 一种五元杂芳环衍生物及其制备方法和用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051723A (https=) 1962-04-27
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
US3252970A (en) 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (https=) 1963-04-26
US3268558A (en) 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
GB1208014A (en) 1967-03-23 1970-10-07 Glaxo Lab Ltd Cephalosporins
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
BE790747A (fr) 1971-10-30 1973-02-15 Whitefin Holding Sa Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (fr) 1976-11-18 1977-03-16 Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent
US4316900A (en) 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
JPH10505584A (ja) 1994-07-21 1998-06-02 イーライ・リリー・アンド・カンパニー インドリジンsPLA▲下2▼インヒビター
US5750540A (en) 1995-04-28 1998-05-12 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
EP0747756B1 (en) 1995-06-06 2000-05-24 Agfa-Gevaert N.V. Photographic materials
JPH09249669A (ja) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
EA008723B1 (ru) 1998-06-03 2007-06-29 Джи-Пи-Ай Эн-Ай-Эл Холдингз, Инк. Аза-гетероциклические соединения, применяемые для лечения неврологических расстройств и выпадения волос
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
ID30409A (id) 1999-05-04 2001-11-29 Jannsen Pharmaceutica N V Eter anti jamur
WO2001008572A1 (de) 1999-07-30 2001-02-08 Norbert Heske Kanülenanordnung zum einbringen endoskopischer instrumente in einen menschlichen oder tierischen körper
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
JP2005501009A (ja) 2001-06-06 2005-01-13 バーテックス ファーマシューティカルズ インコーポレイテッド Cakインヒビターおよびその使用
RU2319699C2 (ru) 2001-06-20 2008-03-20 Дайити Санкио Компани, Лимитед Производные диаминов
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
WO2003072028A2 (en) 2002-02-23 2003-09-04 Bristol-Myers Squibb Company Method of treating hiv infection by preventing interaction of cd4 and gp120
US20050255164A1 (en) 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
US20050032871A1 (en) 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
WO2004082606A2 (en) 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
RU2006117635A (ru) 2003-10-24 2007-12-10 Шеринг Акциенгезельшафт (De) Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование
CA2568007A1 (en) 2004-05-28 2005-12-08 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
WO2006082518A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
JP5023054B2 (ja) 2005-03-31 2012-09-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としての二環式ピラゾール化合物
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
JP5172661B2 (ja) 2005-05-18 2013-03-27 エフ2ジー リミテッド 抗真菌剤
WO2007009083A2 (en) 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007109605A2 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
JP5508859B2 (ja) 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
CN101260086B (zh) 2007-03-06 2011-08-10 中国科学院上海药物研究所 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途
GB0710121D0 (en) 2007-05-25 2007-07-04 F2G Ltd Antifungal agents
US20100215747A1 (en) 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
AU2009239778B2 (en) 2008-04-24 2014-03-13 F2G Ltd Pyrrole antifungal agents
GB0809773D0 (en) 2008-05-29 2008-07-09 F2G Ltd Antifungal combination therapy
US20100093872A1 (en) 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CN102421435A (zh) 2009-04-28 2012-04-18 贝林格尔.英格海姆国际有限公司 使用PKC-θ抑制剂的免疫性疾病的离体治疗
JP5792807B2 (ja) 2010-06-14 2015-10-14 ダウ グローバル テクノロジーズ エルエルシー アセテートおよびサクシネートの置換が向上されたヒドロキシプロピルメチルセルロースアセテートサクシネート
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
EP2636409A1 (en) 2010-11-05 2013-09-11 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
CA2778748A1 (en) 2011-06-01 2012-12-01 Nitto Denko Corporation Particulate preparation and method for producing the same
SG11201401597TA (en) 2011-11-29 2014-05-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
CN104427979B (zh) 2012-04-11 2018-02-16 陶氏环球技术有限责任公司 具有特定的取代基分布的酯化的纤维素醚
MX2015002430A (es) 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
KR102138546B1 (ko) 2012-08-24 2020-07-28 다우 글로벌 테크놀로지스 엘엘씨 부분적으로 가교결합된 에스테르화된 셀룰로즈 에테르
WO2014114575A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
WO2015007759A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP3076951B1 (en) 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
DK3221308T3 (en) * 2014-11-21 2018-12-10 F2G Ltd Antifungals
GB201609222D0 (en) * 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation

Similar Documents

Publication Publication Date Title
ES2390661T5 (es) Forma de presentación para administración por vía oral para éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o sus sales
TWI540128B (zh) 醫藥組合物
CN1886120B (zh) 用于制备可口腔给药的固态药物组合物的方法
ES2988678T3 (es) Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
CN106255496B (zh) 包括紫杉烷的无定形固体分散体、包括其的片剂以及用于制备其的方法
RU2489149C2 (ru) Стабилизированные аморфные формы иматиниба мезилата
JP2019524883A5 (https=)
JP2014523445A5 (https=)
JP2009530415A5 (https=)
WO2017140254A1 (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
JP2008533007A5 (https=)
JP2019516765A5 (https=)
JP2014525449A5 (https=)
JP2024544572A (ja) Rock2阻害剤のナノ結晶製剤およびその調製方法
RU2018142381A (ru) Фармацевтический препарат
CN105358149A (zh) 粉防己碱家族的药物制剂和方法
CN101827584A (zh) N-芳基脲基药物的固态分散体产品
JP2018502118A (ja) 非晶質ヘミフマル酸テノホビルアラフェナミドおよびその予備混合物を調製するプロセス
KR101282847B1 (ko) 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
CN101190912A (zh) 新的抗病毒化合物及其制备方法
KR102276281B1 (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
CN107072954B (zh) 用于口服给药的包含洛贝格列酮的药物组合物
TWI558400B (zh) 苯基尿嘧啶化合物之調配物
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法
JP2015189677A (ja) ソリフェナシン非晶質体を含有する医薬組成物